Basics Novavax, Inc. Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. IPO Date: December 13, 1995 Sector: Healthcare Industry: Biotech Market Cap: $1.28B Activated in VL: True Average Daily Range Avg Daily Range: $0.82 | 3.62% Avg Daily Range (30 D): $0.25 | 3.13% Avg Daily Range (90 D): $0.21 | 2.89% Institutional Daily Volume Avg Daily Volume: 3.99M Avg Daily Volume (30 D): 7.54M Avg Daily Volume (90 D): 7.58M Trade Size Avg Trade Size (Sh.): 196 Avg Trade Size (Sh.) (30 D): 174 Avg Trade Size (Sh.) (90 D): 177 Institutional Trades Total Inst.Trades: 8,652 Avg Inst. Trade: $3.54M Avg Inst. Trade (30 D): $1.71M Avg Inst. Trade (90 D): $1.7M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $6.76M Avg Closing Trade (30 D): $2.81M Avg Closing Trade (90 D): $2.65M Avg Closing Volume: 225.49K     News Aug 12, 2025 @ 5:41 PM CDC Shooting Linked To Suspect's COVID-19 Vaccine ... Source: Vandana Singh Jun 30, 2025 @ 1:51 PM Moderna's mRNA Flu Vaccine Outperforms Standard Sh... Source: Vandana Singh Jun 29, 2025 @ 6:08 PM Vaccine Adjuvants Market to Reach USD 5.43 Billion... Source: Sns Insider Jun 2, 2025 @ 12:35 PM Moderna's New COVID Vaccine Secures FDA-Clearance ... Source: Vandana Singh May 27, 2025 @ 4:29 PM Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine... Source: Vandana Singh Financials   TTM Q2 2025 Q1 2025 Basic EPS $2.6 $.66 $3.22 Diluted EPS $2.27 $.62 $2.93 Revenue $ 1.08B $ 239.24M $ 666.66M Gross Profit $ 951.99M $ 223.92M $ 652.54M Net Income / Loss $ 422.82M $ 106.51M $ 518.65M Operating Income / Loss $ 351.49M $ 101.07M $ 515.51M Cost of Revenue $ 126.73M $ 15.33M $ 14.12M Net Cash Flow $ -426.58M $ -9.5M $ -266.81M PE Ratio 3.41     Splits May 10, 2019:   1:20